XTRA:BAYNPharmaceuticals
Assessing Bayer (XTRA:BAYN) Valuation After New Prostate Cancer Data And Earnings Focus
Oncology data moves into focus for Bayer stock
Bayer (XTRA:BAYN) has drawn fresh attention after presenting new prostate cancer data at ASCO GU 2026, including Phase III results for XOFIGO and early Phase I outcomes for its targeted alpha therapy 225Ac-PSMA-Trillium.
The company reported a 24% reduction in risk of death when XOFIGO was combined with enzalutamide versus enzalutamide alone in men with metastatic castration resistant prostate cancer and bone metastases. Median overall survival...